Artiva Biotherapeutics Inc (ARTV) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing...

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage...

Form 8-K - Current report

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage...

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment...

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission...